Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

540 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.
Borghese C, Casagrande N, Pivetta E, Colombatti A, Boccellino M, Amler E, Normanno N, Caraglia M, De Rosa G, Aldinucci D. Borghese C, et al. Among authors: caraglia m. Oncotarget. 2017 Jun 27;8(26):42926-42938. doi: 10.18632/oncotarget.17216. Oncotarget. 2017. PMID: 28477013 Free PMC article.
The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL. Facchini G, et al. Among authors: caraglia m. J Exp Clin Cancer Res. 2007 Sep;26(3):307-12. J Exp Clin Cancer Res. 2007. PMID: 17987788 Clinical Trial.
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial.
Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, Striano S, Marra L, Nasti G, Ferrari E, Leopardo D, Vitale G, Gentilini D, Tortoriello A, Catalano A, Budillon A, Perrone F, Iaffaioli RV. Facchini G, et al. Among authors: caraglia m. Cancer Biol Ther. 2010 Sep 15;10(6):543-8. doi: 10.4161/cbt.10.6.12611. Epub 2010 Sep 8. Cancer Biol Ther. 2010. PMID: 20657175 Free article. Clinical Trial.
Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda MI, Leonetti C, Caraglia M, De Rosa G. Salzano G, et al. Among authors: caraglia m. Int J Pharm. 2011 Jan 17;403(1-2):292-7. doi: 10.1016/j.ijpharm.2010.10.046. Epub 2010 Nov 3. Int J Pharm. 2011. PMID: 21055454
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes.
Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, Tagliaferri P, Caraglia M, De Rosa G. Marra M, et al. Among authors: caraglia m. Nanomedicine. 2011 Dec;7(6):955-64. doi: 10.1016/j.nano.2011.03.004. Epub 2011 Mar 29. Nanomedicine. 2011. PMID: 21453789
540 results